STLN

SEC source: 0001799191-22-000039 · edgardoc.xml · nonDerivative · entry 1

Pacala Mark L · CIK 0001321250 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,780

SEC source: 0001799191-22-000038 · edgardoc.xml · nonDerivative · entry 1

O'Meara Maeve · CIK 0001742487 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,700

F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date.

SEC source: 0001799191-22-000037 · edgardoc.xml · derivative · entry 2

Miller Matthew P · CIK 0001915822 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,825

Underlying: Common Stock · 119,825 shares

Expires 2032-11-17

F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001799191-22-000037 · edgardoc.xml · nonDerivative · entry 1

Miller Matthew P · CIK 0001915822 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,641

F1 · price: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001799191-22-000036 · edgardoc.xml · nonDerivative · entry 1

McGeorge Anne · CIK 0001779934 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,099

F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date.

SEC source: 0001799191-22-000034 · edgardoc.xml · nonDerivative · entry 1

Kaushal Mohit · CIK 0001683021 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,242

F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date.

SEC source: 0001799191-22-000033 · edgardoc.xml · nonDerivative · entry 1

Johnson Karen Marie · CIK 0001892819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,500

F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date.

SEC source: 0001799191-22-000032 · edgardoc.xml · derivative · entry 2

Hively Brad · CIK 0001891124 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,188

Underlying: Common Stock · 525,188 shares

Expires 2032-11-17

F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001799191-22-000032 · edgardoc.xml · nonDerivative · entry 1

Hively Brad · CIK 0001891124 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 555,670

F1 · price: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001799191-22-000060 · edgardoc.xml · nonDerivative · entry 1

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,193

F1 · shares: This amendment is filed to correct the number of restricted stock units granted due to an administrative error in applying the grant amount calculations.

F2 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date.

SEC source: 0001799191-22-000016 · edgardoc.xml · nonDerivative · entry 1

Virnich Daniel · CIK 0001891107 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,484

F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000015 · edgardoc.xml · nonDerivative · entry 1

Simoneit Diona · CIK 0001921432 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,318

F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000014 · edgardoc.xml · nonDerivative · entry 1

Podnos Yale · CIK 0001891104 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,083

F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.020 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000013 · edgardoc.xml · nonDerivative · entry 1

Miller Matthew P · CIK 0001915822 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,034

F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.022 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000012 · edgardoc.xml · nonDerivative · entry 1

Hively Brad · CIK 0001891124 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,201

F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000054 · edgardoc.xml · nonDerivative · entry 1

Virnich Daniel · CIK 0001891107 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,484

F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000053 · edgardoc.xml · nonDerivative · entry 1

Simoneit Diona · CIK 0001921432 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,318

F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000052 · edgardoc.xml · nonDerivative · entry 1

Podnos Yale · CIK 0001891104 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,083

F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.020 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000051 · edgardoc.xml · nonDerivative · entry 1

Miller Matthew P · CIK 0001915822 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,034

F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.022 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000050 · edgardoc.xml · nonDerivative · entry 1

Hively Brad · CIK 0001891124 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,201

F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0001799191-22-000006 · edgardoc.xml · nonDerivative · entry 1

Kaushal Mohit · CIK 0001683021 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,534

F1 · kind: The sale was pursuant to Mohit Kaushal's Rule 10b5-1 Trading Plan that was established on August 25, 2022.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 14, 2022 within a one-dollar range. Actual prices ranged from $2.08 to $2.18. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-035946 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,362,873

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.16 to $2.74, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-035588 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,728,194

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.62 to $3.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-035588 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,789,475

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.91 to $3.23, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-035588 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,869,475

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.06 to $3.38, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-035320 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,896,475

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.39, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-035320 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,915,642

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.57, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-035320 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,965,842

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.46 to $3.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034844 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,011,342

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $4.17, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034844 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,069,842

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.08 to $4.69, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034844 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,120,114

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.83, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034501 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,161,969

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $5.03, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034501 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,214,060

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.95 to $5.16, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034501 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,249,060

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.94 to $5.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034156 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,301,560

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.34, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-034156 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,331,960

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $5.35, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0001628280-22-027011 · wf-form4_166674432949922.xml · nonDerivative · entry 1

Kaushal Mohit · CIK 0001683021 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,528

F1 · kind: The sale was made pursuant to Mohit Kaushal's Rule 10b5-1 Trading Plan that was established on August 25, 2022.

F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on October 24, 2022 within a one-dollar range. Actual prices ranged from $4.62 to $5.18. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-034156 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,361,360

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $5.12, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033908 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,381,360

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.51 to $5.12, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033908 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,393,360

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.82, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033908 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,410,860

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.44 to $4.92, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033713 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,423,060

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.74, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033713 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,431,309

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.22 to $4.77, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033713 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,441,109

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.77, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033524 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,466,309

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.86, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any Security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033524 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,480,652

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 to $4.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033524 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,505,652

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.01 to $4.61, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033327 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,527,152

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.51 to $4.73, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-033327 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,541,804

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.84, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 8

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,024

Underlying: Common stock · 73,024 shares

Expires not disclosed

F6 · security: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control.

F6 · derivative.exercise_price: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control.

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F5 · derivative.exercise_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation.

F6 · derivative.exercise_date: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control.

F5 · derivative.expiration_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation.

F6 · derivative.expiration_date: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control.